Literature DB >> 32522719

Retrobulbar chlorpromazine injection in a child with gliosarcoma invasion into the orbits.

Franklin Jeng1, Andrew Reynolds2.   

Abstract

This paper has two main purposes: (1) to report a rare case of paediatric gliosarcoma that invaded the surrounding orbit and (2) to demonstrate chlorpromazine injection as a potential treatment option for blind, painful eye caused by tumour invasion. A 12-year-old man who presented with headaches was found to have glioblastoma multiforme and it was excised and treated with radiation and chemotherapy. Seven months later, the tumour recurred as gliosarcoma, a rare variant of glioblastoma multiforme containing distinct gliomatous and sarcomatous components. In spite of treatment, the tumour progressed and eventually invaded into the right orbit. He subsequently developed a proptotic, blind, painful eye and was treated with retrobulbar chlorpromazine injection, which provided immediate symptomatic relief. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  blind; chlorpromazine; gliosarcoma; invasion; retrobulbar

Mesh:

Substances:

Year:  2020        PMID: 32522719      PMCID: PMC7287501          DOI: 10.1136/bcr-2019-233394

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

Review 1.  A review of nasal, paranasal, and skull base tumors invading the orbit.

Authors:  Morten Jørgensen; Steffen Heegaard
Journal:  Surv Ophthalmol       Date:  2017-07-22       Impact factor: 6.048

2.  Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide.

Authors:  Supriya Mallick; Ajeet Kumar Gandhi; Daya Nand Sharma; Subhash Gupta; Kunhi P Haresh; Goura Kishor Rath; Pramod Kumar Julka
Journal:  Childs Nerv Syst       Date:  2015-10-05       Impact factor: 1.475

3.  [Retrobulbar injection of chlorpromazine in the absolute glaucoma (author's transl)].

Authors:  C Fiore; G Lupidi; G Santoni
Journal:  J Fr Ophtalmol       Date:  1980       Impact factor: 0.818

4.  Periocular inflammation after retrobulbar chlorpromazine (thorazine) injection.

Authors:  Timothy J McCulley; Robert C Kersten
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2006 Jul-Aug       Impact factor: 1.746

5.  [Symptomatic treatment of terminal painful glaucoma by the retrobulbar administration of aminazine].

Authors:  N I Bastrikov
Journal:  Vestn Oftalmol       Date:  1989 Sep-Oct

6.  Retrobulbar chlorpromazine injections for the management of blind and seeing painful eyes.

Authors:  Teresa C Chen; Sonia J Ahn Yuen; Marither A Sangalang; Ronaldo E Fernando; Edgar U Leuenberger
Journal:  J Glaucoma       Date:  2002-06       Impact factor: 2.503

Review 7.  Secondary gliosarcoma: a review of clinical features and pathological diagnosis.

Authors:  Seunggu J Han; Isaac Yang; Tarik Tihan; Susan M Chang; Andrew T Parsa
Journal:  J Neurosurg       Date:  2010-01       Impact factor: 5.115

8.  Clinical and epidemiological characteristics of pediatric gliosarcomas.

Authors:  Michael Karremann; Ulrike Rausche; Gudrun Fleischhack; Michaela Nathrath; Torsten Pietsch; Christof M Kramm; Johannes E A Wolff
Journal:  J Neurooncol       Date:  2009-10-06       Impact factor: 4.130

9.  Treatment of patients with painful blind eye using stellate ganglion block.

Authors:  Tatiana Vaz Horta Xavier; Thiago Robis de Oliveira; Tereza Cristina Bandeira Silva Mendes
Journal:  Braz J Anesthesiol       Date:  2014-04-06

10.  Gliosarcoma with Primary Skull Base Invasion.

Authors:  Quoc-Bao D Nguyen; Avital Perry; Christopher S Graffeo; Cody L Nesvick; Aditya Raghunathan; Mark E Jentoft; Brian P O'Neill; Padraig P Morris; Jonathan M Morris; Jamie J Van Gompel
Journal:  Case Rep Radiol       Date:  2016-12-08
View more
  1 in total

1.  Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literature.

Authors:  Nasir Ud Din; Hira Ishtiaq; Shabina Rahim; Jamshid Abdul-Ghafar; Zubair Ahmad
Journal:  BMC Pediatr       Date:  2021-02-26       Impact factor: 2.125

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.